After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...

The phase IIb study results of Supernus Pharmaceuticals Inc.’s SPN-820 in treatment-resistant depression had pulled the company’s stock (NASDAQ:SUPN) down 15.6% on Feb. 19. The randomized, ...

Investigational drug SPN-820, which activates the mTORC1 pathway, failed to significantly reduce depressive symptoms compared ...

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an ...

Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...

Supernus Pharmaceuticals (NASDAQ:SUPN) stock drops as depression candidate SPN-820 misses main goals in Phase 2b trial. Read more here.

Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS ...

Shares of Supernus slid after the company it failed to meet the primary endpoint in its Phase 2b study of SPN-820 in adults with treatment resistant depression.

Supernus (SUPN) announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically ...